TARS
TARSUS Closes Alkeus Deal, Adding Phase 3 Stargardt Drug
Tarsus Pharmaceuticals has completed its acquisition of Alkeus, gaining worldwide rights to oral Stargardt disease candidate gildeuretinol.
TARS
Market-moving news on Tarsus Pharmaceuticals (NASDAQ: TARS): filings, earnings, deals and other events, from REDFILED.